A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
Public ClinicalTrials.gov record NCT00548548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or metastatic gastric cancer who had not received prior chemotherapy for advanced or metastatic disease.
Study identification
- NCT ID
- NCT00548548
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 774 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Capecitabine Drug
- Cisplatin Drug
- Placebo Drug
- 5-fluorouracil Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2007 (Actual)
- Primary completion
- Nov 2009 (Actual)
- Completion
- Nov 2013 (Actual)
- Last update posted
- Jun 14, 2017
2007 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tower Cancer Research Fnd | Beverly Hills | California | 90211-1850 | — |
| Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| Kenmar Research Institute LLC | Los Angeles | California | 90057 | — |
| USC/Norris Cancer Center | Los Angeles | California | 90089 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| H. Lee Moffitt Cancer | Tampa | Florida | 33612 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214-3728 | — |
| Methodist Cancer Center Onc | Omaha | Nebraska | 68114 | — |
| Memorial Sloan Kettering | New York | New York | 10021 | — |
| Duke Univ Medical Center | Durham | North Carolina | 27710 | — |
| South Carolina Oncology Assoc | Columbia | South Carolina | 10595 | — |
| The Sarah Cannon Research Inst | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00548548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00548548 live on ClinicalTrials.gov.